Published in Volume
119, Issue 9 (September 1, 2009)
J Clin Invest. 2009;119(9):2843–2843.
doi:10.1172/JCI35449C1.
Copyright © 2009, American Society for Clinical
Investigation
Corrigendum
CTLs are targeted to kill β cells in patients with type 1
diabetes through recognition of a glucose-regulated preproinsulin
epitope
Ania Skowera, Richard J. Ellis, Ruben Varela-Calviño, Sefina Arif, Guo Cai Huang, Cassie Van-Krinks, Anna Zaremba, Chloe Rackham, Jennifer S. Allen, Timothy I.M. Tree, Min Zhao, Colin M. Dayan, Andrew K. Sewell, Wendy W. Unger, Jan W. Drijfhout, Ferry Ossendorp, Bart O. Roep and Mark Peakman
Published September 1, 2009
Original citation: J. Clin. Invest.
118:3390–3402 (2009). doi:10.1172/JCI35449.
Citation for this corrigendum: J. Clin. Invest.
119:2843 (2009). doi:10.1172/JCI35449C1.
During the preparation of the manuscript, Wendy W. Unger’s name was inadvertently
presented incorrectly in the author list. The correct author list appears above.
The authors regret the error.
